Use of Long Read Genome Sequencing in Patients Suffering From Neurodevelopmental Troubles

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-19

Study Completion Date

2024-03-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with neurodevelopmental diseases and their families need to identify the genetic cause of the disease to allow for recognition of the disability, genetic counseling, and possible hope for participation in therapeutic research studies. Access to high-throughput genomic exome or genome analysis allows the identification of a genetic cause for approximately half of the patients. However, families with no result or with a variant of unknown significance after these tests may find themselves in a new diagnostic impasse.

The high-throughput sequencing used today generates sequences of the order of 100 base pairs (so-called "short read" sequencing). This allows an analysis of about 90% of the genome. However, many regions are not accessible in regions of interest for the genetic diagnosis of rare diseases. Long fragment sequencing generates sequences that are about 20 times larger and its use has recently made it possible to sequence the human genome almost completely (https://www.science.org/doi/10.1126/science.abj6987). The main contribution lies in the analysis of complex regions of the genome such as segmental duplications or centromeric regions. It is likely that this technology increases the sensitivity of detection of genetic variants in patients with genetic diseases. Its contribution should be studied in patients for whom no genetic cause has been identified by classical techniques.

This study aim to investigate the contribution of long fragment genome sequencing.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transcriptomic Approach for the Identification and Prioritization of Genome Variants in Neurodevelopmental Disorders With Malformation

NCT06762678

Neurodevelopmental Disorders and Developmental Abnormalities

NOT_YET_RECRUITING NA

Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic

NCT02136849

Severe Intellectual Disability

COMPLETED

Prospective Study to Assess Medical Performance of Optical Mapping and Long Read Sequencing in Detecting Numerical and Structural Chromosome Abnormalities

NCT05290051

Infertility Intellectual Disability Malformation +1 more

RECRUITING NA

Genome Sequencing Strategies for Genetics Diagnosis of Patients With Intellectual Disability

NCT04154891

Intellectual Disability

COMPLETED NA

Contribution of High Throughput RNA Sequencing Combined With Sequencing of Whole Genomes in the Diagnosis of Intellectual Disability

NCT03857997

Patients With Intellectual Disabilities Without an Obvious Clinical Diagnosis Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ten families with a child suffering from a neurodevelopmental disease will be recruited by geneticists being part of the CLAD-Ouest. An EDTA blood sample will be taken from the patient and their parents (trio analysis). The blood samples will then be used to extract nucleic acids (DNA).

The blood samples will be sent and centralized to the genetics laboratory of the Nantes University Hospital. The DNA will be extracted and anonymized.

The files generated after DNA sequencing will have as an identification key the anonymization number provided at the time of inclusion of the individual in the study. The raw data and VCF files will be uploaded to the BIRD computing cluster in Nantes, where they will be stored for the duration of the study (2 years). The different university hospitals will then be able to retrieve the data and analyze the variants identified in the patients recruited by their center. A centralized analysis to annotate, filter and interpret the variants will be performed by a group of bioinformaticians and biologists from HUGO (University Hospital from the Grand Ouest). Long-term archiving of the data will be performed at the Nantes University Hospital.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Genetic Disease Neurologic Disorder Developmental Delay Disorder Growth Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants

Patients with neurodevelopmental disease and their both parents

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient (child or adult) presenting neurodevelopmental troubles strongly suspected to suffer from a rare genetic disease (familial or very severe).
* Negative outcome for short read sequencing of the trio (child and parents).
* Informed consent to the study by the patient (if applicable) or their legal representatives if under-aged or under guardianship.
* Patients benefiting from the social security (French health care system).

* Informed consent form signed for their own participation.
* Parents benefiting from the social security (French health care system).

Exclusion Criteria

* Genetic predisposition already identified explaining the disease.
* Paients for which the WGS for the trio has not been performed.
* Patients having withdrawn their consent.

* Pregnant or lactating woman.
* Parents under guardianship or curatorship.
* Parents also presenting a neurodevelopmental deficiency.

Eligible Sex

ALL

Accepts Healthy Volunteers

No